A5027982453- Estrogen and related hormone effects
- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Cancer Cells and Metastasis
- HER2/EGFR in Cancer Research
- Immunotherapy and Immune Responses
- Lung Cancer Research Studies
- Immune cells in cancer
- T-cell and Retrovirus Studies
- Animal Disease Management and Epidemiology
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Vector-Borne Animal Diseases
- Hepatitis Viruses Studies and Epidemiology
- Peptidase Inhibition and Analysis
- Cell Adhesion Molecules Research
- Vitamin D Research Studies
- Cancer Research and Treatments
- Cytokine Signaling Pathways and Interactions
- Hormonal and reproductive studies
- Chemokine receptors and signaling
- Cancer, Stress, Anesthesia, and Immune Response
- Calpain Protease Function and Regulation
- S100 Proteins and Annexins
- Advanced Breast Cancer Therapies
Consejo Nacional de Investigaciones Científicas y Técnicas
2012-2025
Experimental Medicine and Biology Institute
2019-2025
University of Buenos Aires
2013-2021
Instituto de Investigaciones Biomédicas en Retrovirus y Sida
2013-2015
Progression to hormone‐independent growth leading endocrine therapy resistance occurs in a high proportion of patients with estrogen receptor alpha (ERα) and progesterone receptors (PR) positive breast cancer. We others have previously shown that estrogen‐ progestin‐induced tumor requires ERα PR interaction at their target genes. Here, we show fibroblast factor 2 (FGF2)‐induces cell proliferation through activation the MYC enhancer proximal promoter. inhibitors, antiestrogens or...
Abstract Purpose: Preclinical data suggest that antiprogestins inhibit the growth of luminal breast carcinomas express higher levels progesterone receptor isoform A (PRA) than B (PRB). Thus, we designed a presurgical window opportunity trial to determine therapeutic effects mifepristone in patients with cancer, based on their high PRA/PRB ratio (MIPRA; NCT02651844). Patients and Methods: Twenty > 1.5 (determined by Western blots), PR ≥ 50%, naïve from previous treatment, were included...
The role of active antitumor immunity in hormone receptor-positive (HR
Background: indeterminate Western blot (WB) patterns are a major concern for diagnosis of human T-cell lymphotropic virus type 1 (HTLV-1) infection, even in non-endemic areas. Objectives: (a) to define the prevalence WB among different populations from Argentina; (b) evaluate if low proviral load (PVL) is associated with profiles; and (c) describe mutations LTR tax sequence these cases. Results: Among 2031 samples, 294 were reactive by screening. Of them, 48 (16.3%) those 15 (31.3%) PCR+....
Abstract Progesterone receptors (PRs) ligands are being tested in luminal breast cancer. There mainly two PR isoforms, PRA and PRB, their ratio (PRA/PRB) may be predictive of antiprogestin response. Our aim was to investigate: the impact isoform on metastatic behaviour, paired primary tumours lymph node metastases (LNM) and, effect antiprogestin/progestins growth. Using murine human models, we demonstrated that with PRB > (PRB‐H) have a higher proliferation index but less ability than...
Although the detection of HTLV antibodies became mandatory in Argentinean blood banks since 2005, there is no recommendation on how to perform screening. As a consequence, variable number false positives depending kit used. The aim present study was evaluate performance six commercial screening tests available currently for initial diagnosis HTLV-1/2 infection South America. positive panel included 14 HTLV-1 and 13 HTLV-2 samples confirmed by WB (HTLV-1/2 MP Diagnostics). negative 233...
Human T-lymphotropic virus 1/2 (HTLV-1/2), hepatitis B (HBV), and D (HDV) share transmission routes. Argentina shows low prevalence of HTLV-1/2, HBV, HDV infections; however, this situation may vary according to the geographic region group studied. The aim study was estimate HBV infections detect both viral genotypes in HTLV-1/2 individuals from Argentina. A total 202 confirmed samples (blood donors [BD] with risk factors for [RF]) were tested HBsAg anti-HBc by enzyme-linked immunosorbent...
Abstract Background: Different antiprogestins have been clinically evaluated in gynecological andbreast cancers. Mifepristone (MFP), as well onapristone and telapristone acetate, showedpartial responses breast cancer clinical trials. Preclinical data indicates that antiprogestinsinhibit cell proliferation of luminal carcinomas expressing higher levels progesteronereceptor isoform A (PRA) than those B (PRB) by western blots (WB). Thus,we designed a pre-surgical window trial to determine the...
HTLV-1 infects about 20 million people worldwide and is considered the etiologic agent of Adult T-cell Leukemia/Lymphoma (ATLL) Associated Mielopathy/Tropical Spastic Paraparesis (HAM/TSP). There still no effective therapy for none pathologies. Porcine cerebral cortex GM1 monosialoganglioside (SINAXIAL®) being prescribed traumatic or acute peripheral neuropathies, cerebrovascular others. CD4 modulation inhibition HIV-1 infectivity induced by in vitro has been published although effect was...
HTLV-1 is the etiologic agent of Adult T-cell Leukemia/Lymphoma (ATLL) and Associated Mielopathy/Tropical Spastic Paraparesis (HAM/TSP). Tax, a critical viral factor for genomic activation gene expression, has been implied in cell transformation. The aim this study was to analyze presence nucleotide polymorphisms tax positive cases from different populations Argentina. A total 85 samples were analyzed: 10 Kollas Jujuy 75 residents Buenos Aires province (BA) which included asymptomatic...
<div>Abstract<p>The role of active antitumor immunity in hormone receptor–positive (HR<sup>+</sup>) breast cancer has been historically underlooked. The aim this study was to determine the contribution immune system antiprogestin-induced tumor growth inhibition using a hormone-dependent model. BALB/c-GFP<sup>+</sup> bone marrow (BM) cells were transplanted into immunodeficient NSG mice generate an immunocompetent NSG/BM-GFP<sup>+</sup> (NSG-R)...
<p>Supplementary Materials and methods</p>
<p>Supplementary Figure 2. MFP induces tissue remodeling in tumors growing NSG-R mice.</p>
<p>Supplementary Figure 4. 59-2-HI tumors express PD-L1 and MFP treatment upregulates expression in CD45neg cells F4/80+ macrophages vivo</p>
<p>Supplementary Figure 3: MFP treatment reduced MDSCs frequency in the TME and spleen</p>
<div>AbstractPurpose:<p>Preclinical data suggest that antiprogestins inhibit the growth of luminal breast carcinomas express higher levels progesterone receptor isoform A (PRA) than B (PRB). Thus, we designed a presurgical window opportunity trial to determine therapeutic effects mifepristone in patients with cancer, based on their high PRA/PRB ratio (MIPRA; NCT02651844).</p>Patients and Methods:<p>Twenty > 1.5 (determined by Western blots), PR ≥ 50%, naïve from...
<div>AbstractPurpose:<p>Preclinical data suggest that antiprogestins inhibit the growth of luminal breast carcinomas express higher levels progesterone receptor isoform A (PRA) than B (PRB). Thus, we designed a presurgical window opportunity trial to determine therapeutic effects mifepristone in patients with cancer, based on their high PRA/PRB ratio (MIPRA; NCT02651844).</p>Patients and Methods:<p>Twenty > 1.5 (determined by Western blots), PR ≥ 50%, naïve from...
<p>Mutations identified in RNA-Seq analysis. The data obtained studies were graphed using the Oviz-Bio tool (https://academic.oup.com/nar/article/48/W1/W415/5835823). Only driver breast cancer genes (99) selected from Intogene base (https://www.intogen.org/download) and we found mutations 19 after read depth filtering (DP >50). Of note is missense mutation ESR1 M070 patient. Left, Percentage of samples with mutations. Color defines type mutations.</p>
<p>Morphological features after mifepristone treatment. A-D, Images illustrating increased stromal tissue (A), thin and scarce collagen fibers, matrix (arrow; B), an area of remodeling (C), differentiation (D) observed in the surgical samples (S) compared to respective core needle biopsies (CNB). E, Image illustrates necrosis (dotted arrow) together with a differentiated structure (black sample. F, Cells Alcian blue+ (left), PAS+ (middle) MUC-1+ (immunohistochemistry; right) vacuoles...
<p>A, Prevailing PR isoforms before and after mifepristone treatment their prevailing nuclear (Nuc) or cytosolic (Cyt) localization in western blot studies. *: Western studies; #: Distribution of the Nuc Cyt compartments; CNB: Core needle biopsy, S: Surgical sample. In grey font: Mifepristone unresponsive tumors by Ki67 criteria. B, Representative blots CNB surgical samples from all patients. The upper band is PRB lower PRA, as labeled first set.</p>